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Abstract
Notoedric mange (feline scabies) is a rare, but high-
ly contagious disease of cats and kittens caused 
by Notoedres cati (N. cati), which can infest other 
animals and also humans. The study objective was 
to determine the efficacy and safety of 10 % imi-
dacloprid/1 % moxidectin (Advocate®/Advantage® 
Multi spot-on for cats) against natural N. cati 
infestation in cats. Sixteen cats were randomly 
assigned to treatment group or negative control 
using pre-treatment mite counts. The treatment 
group received a single spot on treatment of the 
investigational veterinary product (IVP) accord-
ing to label instructions. The control group stayed 
untreated. Five cats from the negative control were 
treated with the IVP at the end of the study and 
observed for 28 days to increase the treatment 
group. Skin scrapings and mite counts were per-
formed 28 days post treatment (p.t.). Notoedric skin 
lesion assessments with clinical scoring were per-
formed regularly. Five animals had to be removed 
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prematurely from the study population due to dif-
ferent reasons. The number of viable N. cati mites 
in all treated animals 28 days p.t. was zero com-
pared with 2.8 ± 3.0 in the negative control, being 
significantly lower for treated cats (p = 0.0019, 
Wilcoxon test). The resulting efficacy was 100 %. 
Clinical cure based on skin lesion assessment was 
achieved 28 days p.t. in 100 % of all treated animals 
completing 28 study days.
The IVP was well tolerated and applied at the mini-
mal therapeutic dose (10 mg imidacloprid/1 mg 
moxidectin/kg body weight) a high therapeutic effi-
cacy in curing N. cati infestations and feline scabies 
clinical symptoms was recorded. 
Introduction
Scabies in general is an intensely pruritic, non-sea-
sonal, contagious dermatopathy caused by rather 
species-specific, sarcoptiform mites (Schwartzmann 
1983; Toomey 1922). However, most scabies mites 
are capable of causing dermatitis also in other host 
species. Concerning Notoedres spp., more than 
20 species have been described, most of which are 
ectoparasites of tropical bats (Wall and Shearer 
2000). Apart from bats, Notoedres mites parasitise 
in several other mammalian species. 
Notoedric mange caused by the mite Notoedres 
cati (Astigmata: Sarcoptidae) (Fig. 1) is a cutane-
ous ectoparasitic disease of mammals. This dis-
ease often affects domestic cats (Felis catus), wild 
cats and more rarely it has become a major dis-
ease among wild animals in captivity and natural 
reserves (Valenzula et al. 2000). The condition is 
highly contagious and primarily occurs by direct 
contact between animals or by contact with infest-
ed bedding or sites recently visited by infested ani-
mals. The clinical manifestation is, as in scabies, 
characterised by intense pruritus, hyperkeratosis, 
peeling skin and lesions, especially on the face and 
the ears (Friberg 2006), extending to the neck, 
limbs and other body areas in the case of massive 
infestation (Fig. 2). The clinical symptoms are often 
Fig. 1  Scanning electron micrograph of an adult  
Notoedres cati mite among hair and skin debris
Fig. 2 Cat showing severe notoedric mange symptoms
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aggravated by secondary bacterial infections, initi-
ated by the excoriations from self-trauma (Fadok 
1980), and the disease can even be lethal. Finally 
the mite possesses also a zoonotic potential and has 
been diagnosed in humans after close contact with 
infested animals (Chakrabarti 1986; Fujita et al. 
1997). 
The disease is diagnosed by direct microscopic 
identification of the mite, obtained by superficial 
skin scrapings. A differentiation of this spherical 
mite of approximately 200–350 μm in size from 
Sarcoptes scabiei is based especially on the criteria 
of medium-length, unjointed, sucker-bearing stalks 
on the legs, a greater number of body striations 
and a dorsal anus. N. cati mites excavate burrows 
up to the stratum germinativum, where eggs are 
deposited by the females. Within approximately 
three weeks the developmental cycle is completed 
(Kutzer 2000).
Feline notoedric mange is rather uncommon to 
rare in most western European countries, but in 
regions of Italy, Switzerland, Spain, Slovenia and 
Croatia it is still occurring, either endemic or pre-
sent in an epizootic state (Leone 2007). It has also 
been reported from regions of the former country 
Czechoslovakia (Nesvadba 1967), Poland (Gorski 
et al. 2004), Japan (Fukase et al. 1991), and Brazil 
(Alves Ferreira et al. 2010; Torres Ferreira et al. 
2009) with sometimes high numbers of prevalences 
(20.9 % in northeastern Brazil (Torres Ferreira 
et al. 2009)). Even though often occurring more in 
focal distributions in a restricted number of coun-
tries, the zoonotic potential, the possible severity of 
the clinical disease in animals and the easy trans-
mission between animals emphasises the necessity 
of an effective, reliable and easily applied treat-
ment for cats. 
The treatment of notoedric mange aims to eradi-
cate the mite on the animal (Angarano and Parish 
1994). There are few, if any, treatments currently 
licensed to treat notoedric mange in cats in Europe. 
There are some reports in the literature on the off-
label use of treatment schemes with weekly total 
body lime sulfur dips (Angarano and Parish 1994), 
where animals often had to wear an “Elizabethan 
collar” until dry, or on oral respectively subcutane-
ous application of doramectin (Delucchi and Castro 
2000; Ferrero et al. 1996) or ivermectin (Cozette 
1996; Oliva and Baldi 1988; Fukase et al. 1991). 
More recently single treatments were done with 
other avermectins, e.g. selamectin (Itoh et al. 
2004; Leone et al. 2003), which were reported to 
be successful.
The combination of 10 % imidacloprid/1 % mox-
idectin (Advocate®/Advantage® Multi, Bayer) is a 
registered feline product containing moxidectin 
as a very potential macrocyclic lactone. The cat 
product has been, among others, approved for the 
treatment of Otodectes cynotis and is expected to 
be as effective against N. cati. Moreover, the dog 
product Advocate® spot on for dogs containing 10 % 
imidacloprid/2.5 % moxidectin is approved for the 
treatment of Otodectes cynotis and Sarcoptes scabiei 
infestation (Fourie et al. 2003; Krieger et al. 2005).
The objective of this study was to determine the 
efficacy of a single topical application of Advocate®/ 
Advantage® Multi at the recommended dosage 
(imidacloprid 10 mg/kg body weight and moxidec-
tin 1 mg/kg body weight) in the treatment of cats 
naturally infested with N. cati.
Materials and methods
Study design
The study was conducted as a negative controlled, 
randomised, partially blinded, unicentre study in 
compliance with local regulatory requirements of 
Hungary, Directive 2009/09/EC, Directive 2004/28/
EC amending 2001/82/EC and applying VICH 
Guideline on Good Clinical Practice (GCP), the 
guideline on statistical principles of veterinary 
clinical trials (EMEA/CVMP/816/00-Final) and the 
guideline on demonstration of efficacy of ectopara-
sites (The Rules Governing Medicinal Products in 
the European Union, Volume VII (7AE17a)). This 
study was authorised by the Hungarian regulatory 
authorities prior to implementation.
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Study animals, study procedures and  
efficacy study 
Study animals
The sixteen cats included into the study were cli-
ent-owned European short-hair cats of both sexes, 
between 4 and 60 months of age, apparently healthy 
with the exception of confirmed notoedric mange 
infestation, based on clinical signs and positive 
results for viable N. cati mites on skin scrapings.
Study population
The study population consisted of originally eight 
negative control animals and eight animals treated 
with the investigational veterinary product (IVP) 
(Advocate®/Advantage® Multi – 10 % imidacloprid/ 
1 % moxidectin). On Day 28 (study completion day) 
five animals of the negative control group possess-
ing viable mite counts were treated with the IVP 
two days later (Day 30) and evaluated analogous 
to the eight previously IVP-treated cats until day 
58 in order to increase the number of IVP-treated 
animals. From these five animals results of sample 
collections were evaluated within the IVP group 
using mite counts of Day 28 as baseline counts 
and mite counts of Day 58 as completion counts. 
An analysis of the primary and secondary efficacy 
criteria was performed in these five additionally 
IVP-treated animals in the same way as described 
for the original eight IVP-treated animals. Sum-
marising, the group of animals receiving the IVP 
consisted of 13 cats and the negative control group 
consisted of eight cats. On Day –1 cats were ran-
domly allocated to treatment or negative control 
group by pre-treatment mite counts determined 
on Day –1 in descending order. No randomisation 
was used for the additional five cats enrolled and 
treated with the IVP on Day 30.
Accommodation
Cats were acclimatised to the study site for at least 
four weeks prior to treatment. During this time, 
cats were kept in two separate heated and air 
conditioned rooms. 
In one of these rooms individual cages for eight cats 
of the IVP treatment group were placed. After ran-
domisation and treatment (Day 0) and from Day 
30 onwards (treatment day for the five additional 
cats), the cats were kept in individual cages for 
three days to avoid cross contamination. From Day 
4 respectively Day 34 onwards, IVP treated cats 
were housed together in one room until the end of 
the study. Untreated control cats were also group- 
housed in one room, strictly separated from the IVP- 
treated cats. Cats were provided with commercial 
dry and canned food and water ad libitum. 
Study procedures
Clinical observations
Physical examination including body weighing 
was performed at baseline (Day –1) prior to study 
inclusion, on Day 29 for the five additional cats 
and whenever daily general health observations 
demanded a further physical examination based 
on clinical signs. A final physical examination was 
performed at study completion or at premature 
study removal of an animal. Assessment of notoe-
dric skin lesions and observation of the applica-
tion site was performed on Days –1, 0, 1, 7, 14, 
21 and 28, as well as on Days 30, 31, 37, 44, 51 and 
58 for the five additional cats or any other day of 
study completion, if earlier removal from the study 
was required. For all enrolled cats general health 
observations were performed on a daily basis dur-
ing the whole study duration by observing appetite, 
demeanour, urination and defaecation. 
Skin lesion assessment
For the assessment of notoedric skin lesions, 
severity and extent of the lesions on each cat were 
assessed before and after treatment on the days 
given above along with the following scores. 
Score for severity of notoedric lesions:
0 = no skin lesions, no alopecia, no scratching
1 = mild skin lesions, mild alopecia, occasionally 
scratching
2 =  moderate skin lesion, moderate alopecia, inten-
sive scratching, scratching wounds,
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3 = severe skin lesion, severe alopecia, thick/crusty 
and scabby appearance of the skin, intensive 
scratching, scratching wounds
Score for extension of notoedric lesions:
0 = no skin lesions
1 = < 50 % of the body skin surface affected
2 = ≥ 50 % of the body skin surface affected
Both scores were added up and expressed as a Notoe-
dres-induced skin lesions score (NISLS) with sum 
values between 0 and 5. A final clinical assessment 
of Notoedres-induced skin lesions was performed 
based on NISLS on Day 28 (Day 58 for the five addi-
tional cats) or any other earlier day of removal. 
The following outcomes were possible:
– clinical cure → NISLS reduced to zero
–  clinical improvement → NISLS < 50 % of NISLS 
on Day 0 (Day 30)
–  clinical failure → NISLS ≥ 50 % of NISLS on 
Day 0 (Day 30)
Skin scrapings
Skin scrapings (about 1 cm² each) from three dif-
ferent sites suspected of being infested and subse-
quent mite counts were performed on Days –1 and 
28, and on Days 28 and 58 (for the five further 
cats), respectively, or at premature study removal. 
For laboratory examination these three samples 
from one cat were evaluated as one sample per 
study day.
For the skin scrapings, hair of the cats was removed 
over the sampling areas, and skin scrapings were 
made with a 2-cm blade so that capillary oozing 
occurred. Immediately afterwards the removed 
material (i.e. hair and skin scrapings) was sowed 
in a Petri plate. The plate was kept at 30 °C for 
15 minutes, before counting of the viable mites 
started. After counting of all viable mites and prior 
to the counting of dead mites respectively mite 
eggs, complete material was sowed in 10 % potas-
sium hydroxide (KOH). In general, mites (viable 
and dead) were counted ensuring that the complete 
material collected was observed. 
The quantitative examination was carried out with 
a stereoscope at 40x enlargement. The entire proce-
dure was completed on site (Day 0 and Day 28) or 
in a designed laboratory (Day 58) by blinded labo-
ratory personnel.
Safety criteria
Safety of the IVP was assessed by documenting all 
adverse events during the whole study duration. 
Treatment application
Cats of the treatment group received Advocate® / 
Advantage® Multi spot-on for cats according to 
body weight using the minimum therapeutic dose 
of 0.1 ml/kg body weight on Day 0 (original eight 
cats) or Day 30 (additional five cats). 
In order to keep partial blinding, separate person-
nel for clinical and laboratory examinations were 
used. No deblinding was done for the first study 
period from Day 0 to Day 28. On Day 28, blind-
ing was broken to continue with the five control 
animals possessing positive mite counts for further 
28 days (Day 30 to Day 58).
Statistical analysis
Data were statistically examined using SAS® statis-
tical analysis software of SAS Institute Inc., Cary, 
NC, USA (version 9.2). Summary statistics includ-
ing arithmetic and geometric means, minimum, 
maximum and median were provided for all counts, 
percentages or continuous parameters of interest. 
Primary efficacy objective was to compare the moxi-
dectin-treated group with the negative group with 
respect to parasitological cure (therapeutic efficacy), 
i.e. complete elimination of viable mites (of all three 
life stages) 28 days post treatment (p.t.). Therefore, 
five cats which were removed prematurely from the 
study were excluded from the analysis. Secondary 
efficacy objective was to compare the reduction of 
severity and/or extension of skin lesions caused by 
notoedric mite infestation (clinical cure).
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The criterion for efficacy was the difference between 
the arithmetic means of the treatment group and 
the untreated group 28 days p.t.
Percent efficacy was calculated using arithmetic 
means according to the formula:
 
% efficacy =
100 × (mean viable count [negative control]
– mean viable count [IVP-treated group])
mean viable count [negative control]
 
The following statistical methods were used for 
each evaluation criterion:
Primary efficacy criterion (number of viable mites 
(larvae, nymphs or adults) in skin scrapings) at 
Day 28 or Day 58, with one-sided test of superi-
ority as statistical approach, was calculated with 
Wilcoxon-Mann-Whitney test for the treated group 
vs. the untreated group. 
The secondary efficacy criterion (improvement of 
skin lesions) was calculated separately for each 
post-baseline period in percent animals with 
improvement, worsening and no change. Treat-
ment group was compared using the Mantel-Haen-
szel chi-square statistic.
For the safety criteria (adverse events), treatment 
group comparison using Fisher’s exact test calcu-
lating the number and percentage of animals with 
at least one adverse event was calculated. The level 
of significance was set at p = 0.05, all tests per-
formed were two-sided.
Results
Sixteen cats, which fulfilled the inclusion criteria, 
were enrolled in the study. Eight cats were treated 
with the IVP on Day 0, and five additional cats 
from the negative control group with viable mite 
counts on Day 28 were treated with the IVP on Day 
30, resulting in 13 IVP-treated cats in total, while 
eight cats were grouped in the negative control 
group on Day 0. Five out of these 16 cats (two in the 
IVP-treated group and three in the negative con-
trol) terminated the study earlier than Day 28 due 
to severe notoedric mange (four animals) or other 
reasons (one animal) (see also Safety assessment). 
Analyses of the efficacy criteria were calculated for 
the Per Protocol (PP) population, consisting of all 
animals which completed the 28 study days after 
treatment, i.e. six cats treated on Day 0 plus five 
cats treated on Day 30 and five negative controls.
Efficacy parameters
Primary efficacy criterion – viable mite counts
The primary efficacy criterion in this study was 
the viable mite count post treatment. The individ-
ual mite counts of the study animals are listed in 
Table 1.
The number of viable mites was reduced by 100 % 
in all animals treated with the IVP which complet-
ed 28 study days. For detailed viable mite count 
data and percent efficacies in the different study 
groups see Table 2.
Secondary efficacy criterion – improvement of 
skin lesions
In the PP population, all animals were cured in 
the IVP group (100.0 %) 28 days p.t. compared to 
one animal (20.0 %) in the negative control group 
(p = 0.009; Mantel-Haenszel test). Within the same 
population, first clinical improvement (NISLS 
< 50 % of NISLS on Day 0/Day 30) was observed 
on Day 7 within the IVP group (one animal), and 
first clinical cure (NISLS reduced to zero) was 
observed on Day 14 (one animal in the IVP group). 
For detailed data see Table 3.
Safety assessment
Safety was assessed based on all study animals 
receiving at least one dose of the IVP and all ani-
mals from the negative control group. Adverse 
events which were documented for animals of 
the control group which received the IVP on Day 
30 were evaluated within the IVP-treated group. 
Therefore, safety criteria were evaluated for 13 ani-
mals treated with the IVP compared to eight ani-
mals of the negative control group.
No local reactions at the application site were 
reported. In total, six adverse events were reported 
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Table 1 Viable mite count data of the study animals









7 1 excluded b
8 2 0







10 1 1 0
11 1 1 0
12 7 excluded c
13 13 8 0
14 1 excluded d
15 3 2 0
16 4 excluded e
AM ± SD 4.0 ± 5.1 2.8 ± 3.0 AM ± SD 0.0 ± 0.0
AM ± SD (IVP group 
extended by  
5 additional cats)
0.0 ± 0.0
AM = arithmetic mean; SD = standard deviation; IVP = investigational veterinary product
a excluded Day 4 (death); b excluded Day 25 (death); c excluded Day 0 (death); d excluded Day 7 (removal);  
e excluded Day 2 (removal) 
In the analysis the five cats which were removed prematurely from the study are not included.
Table 2 Overview on mean viable mite counts (arithmetic mean) and percent efficacies in the different study populations 
28 days post treatment
Evaluation population
Mean viable mite count
(IVP-treated group)




(6 IVP, 5 neg. controls)
0.0 2.8 100.0 %
Per Protocol (PP) population
(inclusive 5 additional cats; 11 IVP,  
5 neg. controls)
0.0 2.8 100.0 %
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for six animals – three among three animals (23.1 %) 
in the IVP group and three among three animals 
(37.5 %) in the negative control group. This dif-
ference was not statistically significant (p > 0.6; 
Fisher’s exact test). Three animals died during the 
study, stating a serious adverse event – two from 
the IVP-treated group and one from the negative 
control group. In detail, one cat of the IVP-treated 
group died on Day 4 due to very severe Notoedres 
infestation (clinical symptoms of hypothermia, 
apathy and anorexia). A second cat of the IVP- 
treated group was found dead on Day 25. For both 
cats, results of the pathology examination excluded 
relation with the IVP treatment. The third adverse 
event within the IVP group was observed in one 
cat 24 days p.t. presenting with hypothermia, apa-
thy and anorexia. This cat recovered completely. 
None of these adverse events were suspected to be 
related to the study medication. Within the nega-
tive control group one cat died on Day 0 due to 
a very severe Notoedres infestation with clinical 
symptoms of hypothermia, diarrhoea and dyspnoe. 
Two further cats showed adverse events in form of 
alopecia, apathy and pyodermatitis, respectively 
hypothermia in a very severe state, so that these 
animals were removed from the study for animal 
welfare reasons on Day 2 and Day 7, respectively.
Table 3 Improvement in skin lesions based on NISLS
IVP-treated group (n = 11) Negative control (n = 5)
1 day p.t.
Clinical failure 11 (100.0 %) 5 (100.0 %)
Total 11 (100.0 %) 5 (100.0 %)
7 days p.t.
Clinical improvement 1 (9.1 %) 0 (0.0 %)
Clinical failure 10 (90.9 %) 5 (100.0 %)
Total 11 (100.0 %) 5 (100.0 %)
14 days p.t.
Clinical cure 1 (9.1 %) 0 (0.0 %)
Clinical improvement 1 (9.1 %) 0 (0.0 %)
Clinical failure 9 (81.8 %) 5 (100.0 %)
Total 11 (100.0 %) 5 (100.0 %)
21 days p.t.
Clinical cure 7 (63.6 %) 0 (0.0 %)
Clinical failure 4 (36.4 %) 5 (100.0 %)
Total 11 (100.0 %) 5 (100.0 %)
28 days p.t.
Clinical cure 11 (100.0 %) 1 (20.0 %)
Clinical failure 0 (0.0 %) 4 (80.0 %)
Total 11 (100.0 %) 5 (100.0 %)




N. cati, the feline sarcoptic mite, can infest cats 
of all ages. In severe cases the originally infest-
ed areas of head, ears and neck may change to a 
generalised infestation and might be lethal, if not 
treated. This could also be observed in the under-
lying study, where the general condition of severely 
infested cats deteriorated so much that removal 
from the study was necessary or even death was 
observed. This possible severe disease outcome 
and the zoonotic potential after intensive contact, 
causing papulovesicular lesions accompanied by 
intense pruritus in humans (Chakrabarti 1986), 
emphasise the necessity of an effective treatment in 
cats. Previous treatment schemes using ivermectin 
(e.g. Cozette 1996; Oliva and Baldi 1988; Fukase 
et al. 1991), have been replaced by the off-label use 
of other avermectins (e.g. selamectin). However, in 
many European countries, no product is licensed, 
and especially concerning the use of ivermectin, 
sudden death has been reported in kittens (Merck 
Veterinary Manual 1998).
The product used in the study is a registered prod-
uct for cats. Its efficacy against N. cati infestation 
was proven based on the superiority of the IVP in 
treatment of cats naturally infested with N. cati 
mites compared to an untreated control group. In 
order to increase the sample size and for the rea-
son of animal welfare, five of eight untreated con-
trol cats which still had viable mite counts on Day 
28 were additionally treated with the IVP on Day 30.
Regarding the primary efficacy criterion (i.e. viable 
mite counts p.t.), all IVP-treated cats had negative 
viable mite counts 28 days after treatment result-
ing in 100 % efficacy against N. cati infestation.
Concerning the safety evaluation, it can be conclud-
ed that the IVP treatment was well tolerated in all 
cats and no drug-related adverse events occurred.
However, the data also showed that the treatment 
with 10 % imidacloprid/1 % moxidectin might not 
prevent a serious lethal outcome of a very severe 
notoedric mite infestation; it seems to take more 
than four days to eradicate the mites (positive mite 
count of one IVP-treated cat upon death on Day 4). 
Secondary lesions may even last longer, which 
emphasises the need to start treatment as early 
as possible. 
Concerning the efficacy of a 10 % imidacloprid/1 % 
moxidectin treatment, convincing results were 
achieved in mite count data 28 days after treat-
ment as well as in clinical cure, showing clinical 
cure in 100 % of all animals already 28 days after 
treatment, compared to 80 % clinical failure in the 
negative control group at the same time, thus offer-
ing an effective, safe alternative of notoedric mange 
therapy.
Conclusion
Superiority of the IVP group compared to the 
untreated control group was shown. Considering 
only animals which were observed for the planned 
duration of 28 days (PP population), zero mite 
counts in the IVP group and 2.8 (± 3.0) (arithmetic 
means ± standard deviation) in the untreated con-
trol group (Mann-Whitney statistic = 1; p = 0.0019, 
Wilcoxon test, one-sided) were recorded, resulting 
in a reduction of viable mites by 100 %. 
Clinical scoring documenting clinical cure was first 
observed on Day 14 (one animal). Twenty-eight 
days after treatment, all IVP-treated cats (100 %) 
were clinically cured. 
Ethical standards
The study was conducted as a negative controlled, 
randomised, partially blinded, unicentre study in 
compliance with local regulatory requirements of 
Hungary and in accordance with Good Clinical 
Practice (GCP) standards based on VICH GL9, 
EMEA/CVMP/816/00-Final, Directive 2009/09/
EC, Directive 2004/28/EC amending 2001/82/EC 
and The Rules Governing Medicinal Products in 
the European Union, Volume VII (7AE17a). It was 
authorised by the Hungarian regulatory authori-
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